Renal function impairment

It is important to use the tetracyclines cautiously in patients witii renal function impairment, hi addition, doses greater that 2 g d can be extremely damaging to die liver. The nurse should carefully check die expiration dates of die tetracyclines before administration because degradation of the tetracyclines can occur after degradation, the agents are highly toxic to the kidneys. 

These drug are used cautiously in patients with gastrointestinal disorders, renal function impairment and those who are pregnant or lactating. 

Goldstein, R.S., Noordewier, B., Bond, J.T., Hook, J.B. and Mayor, G.H. (1981). Cis-diaminedichloroplatinum nephrotoxicity Time course and dose response of renal functional impairment. Toxicol. Appl. Pharmacol. 60 163-175. 

Renal function impairment Use with caution. Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication. 

Renal function impairment Renal function impairment requires careful monitoring of the serum potassium concentration and appropriate dosage adjustment. 

Renal function impairment Infusions of sodium ions may result in excessive sodium retention administer with care. 

Renal function impairment No changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite with creatinine clearances ranging from approximately 15 mL/min to more than 100 mL/min if data were corrected for differences in age. Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/min). 

Renal function impairment There is limited experience in patients with renal impairment. No unexpected problems have been encountered in patients having mild renal impairment, and there is no experience with dosage adjustment in patients with greater degrees of renal impairment. Nevertheless, for renally impaired patients it may be necessary to reduce ticlopidine dosage or discontinue it altogether... 

Renal function impairment- AWnough no dose adjustment is recommended in patients with mild (Ccr 50 to 80 mL/min) and moderate (Ccr 30 to 50 mL/min) renal impairment, observe all such patients carefully for signs and symptoms of bleeding. 

Renal function impairment W th renal impairment, relative overdose might occur even with a standard dosage regimen. In patients with marked renal insufficiency (creatinine clearance less than 15 mL/min) and on hemodialysis, elimination half-lives are prolonged 2 days or less. Reduce the bolus dose and rate of infusion in patients with known or suspected renal insufficiency (see Administration and Dosage). 

Renal function Impairment Drug elimination was related to GFR. Clearance was reduced approximately 20% in patients with moderate and severe renal impairment and was reduced approximately 80% in dialysis-dependent patients. 

Renal function impairment The risk of hemorrhage increases with increasing renal impairment. Fondaparinux is contraindicated in patients with severe renal impairment (Ccr less than 30 mL/min). Use with caution in patients with moderate renal impairment (Ccr 30 to 50 mL/min). 

Renal function impairment Less than 0.1 % of a steady-state 0.5 mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment. 

Renal function Impairment Edema may occur in the presence of renal disease with a fixed or decreased glomerular filtration rate. 

Gl Gl symptoms are the most common reactions to miglitol. The incidence of diarrhea and abdominal pain tend to diminish considerably with continued treatment. Renal function impairment Plasma concentrations of miglitol in renally impaired volunteers were proportionally increased relative to the degree of renal dysfunction. Long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine more than 2 mg/dL) have not been conducted. Treatment of these patients with miglitol is not recommended. 

Renal function impairment Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide with the 0.5 mg dose subsequently, carefully titrate patients. 

Renal function impairment Metformin is known to be excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Do not give metformin to patients with serum creatinine levels above the upper limit of normal for their age. 

Renal function impairment- In patients receiving pamidronate for bone metastases who show evidence of deterioration in renal function, withhold treatment until renal function returns to baseline. In a clinical study, renal deterioration was defined as follows for patients with normal baseline creatinine, an increase of 0.5 mg/dL for patients with abnormal baseline creatinine, an increase of 1 mg/dL. In this clinical study, pamidronate treatment was resumed only when the creatinine returned to within 10% of the baseline value. In other indications, clinical judgment should determine whether the potential benefit outweighs the potential risk in such patients. 

Renal function impairment- Upon treatment initiation, the recommended zoledronic acid doses for patients with reduced renal function (mild to moderate renal impairment) are listed in the following table. These doses are calculated to achieve the same AUC as that achieved in patients with Ccr of 75 mL/min. Ccr is calculated using the Cockcroft-Gault formula. 

Renal function impairment There was a statistically significant 27% decrease in plasma clearance of nalmefene in the end-stage renal disease (ESRD) population during interdialysis (0.57 L/h/kg) and a 25% decreased plasma clearance in the ESRD population during intradialysis (0.59 L/h/kg) compared with controls (0.79 L/h/kg). The elimination half-life was prolonged in ESRD patients from 10.2 (controls) to 26.1 hours. 

Renal function impairment In children with renal disease, digoxin must be carefully titrated based upon clinical response. 

Renal function impairment Reduce dosage in impaired renal function. Carefully monitor ECG for signs of overdosage. The controlled-release form is not recommended for patients with severe renal insufficiency (Ccr up to 40 mL/min). Hepatic function impairment Impairment increases plasma half-life reduce dosage in such patients. Carefully monitor the ECG. Patients with cardiac dysfunction have a higher potential for hepatic impairment. 

Renal function impairment The pharmacokinetics of diltiazem and verapamil in patients with impaired renal function are similar to the pharmacokinetic profile of patients with normal renal function. However, caution is still advised. Nifedipine s plasma concentration is slightly increased in patients with renal impairment. Nicardipine s mean plasma concentrations, AUC and maximum concentration were about 2-fold higher in patients with mild renal impairment. 

Renal function impairment- In patients with renal impairment, clearance of betaxolol declines with decreasing renal function. 

Renal function impairment The active metabolites of methyidopa accumulate in uremia. Use with caution in renal failure. Prolonged hypotension has been reported. Hypertension has recurred occasionally after dialysis in patients given methyidopa because the drug is removed by this procedure. 

Renal function impairment Exercise caution when alfuzosin is administered in patients with severe renal insufficiency. 

Renal function impairment In hypertensive patients with normal kidneys who are treated with hydralazine, there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate. Renal function may improve where control values were below normal prior to administration. Use with caution in patients with advanced renal damage. 

Renal function impairment Renal failure or dialysis patients may require smaller doses closely supervise to prevent cardiac failure or exacerbation of renal failure. Carcinogenesis Dietary administration of minoxidil to mice for up to 2 years was associated with an increased incidence of malignant lymphomas in females at all dose levels (10, 25, and 63 mg/kg/day) and an increased incidence of hepatic nodules in males (63 mg/kg/day). 

Renal function impairment - 5 mg once daily in patients with Ccr of less than 30 mL/min/1.73 m (serum creatinine greater than 3 mg/dL). Dosage may be titrated upward until BP is controlled or to a maximum of 40 mg/day. 

Renal function impairment Admn s er 1.25 mg every 6 hours for patients with Cor greater than 30 mL/min. For Ccr 30 mL/min or less, initial dose is 0.625 mg. If there is inadequate clinical response after 1 hour, the 0.625 mg dose may be repeated. May give additional 1.25 mg doses at 6-hour intervals. For dialysis patients, initial dose is 0.625 mg or less administered over 5 minutes or more, preferably longer (no more than 1 hour). 

Renal function impairment- For hypertension, titrate dosage upward until BP is controlled or to a maximum of 40 mg daily. 

Renal function impairment In patients with Ccr of less than 40 mL/min/1.73 m (serum creatinine approximately greater than 2.5 mg/dL) doses only 25% of those normally used should be expected to induce full therapeutic levels of ramiprilat. 

---